Improving delivery of immune therapy for triple-negative breast cancer
Improving the platelet-mediated immune checkpoint inhibitor delivery for treating triple-negative breast cancer
This study is looking at a new way to help patients with triple-negative breast cancer by using platelets to deliver immune treatments directly to the tumor, which could make the treatment work better and help the body fight the cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11049687 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of immune checkpoint inhibitors for patients with triple-negative breast cancer (TNBC), a type of cancer that often does not respond well to standard treatments. The approach involves using a novel system that utilizes platelets to deliver these inhibitors directly to the tumor site, improving their ability to activate the immune response against cancer cells. The study aims to increase the accumulation of this treatment at the tumor site and to modify the surrounding environment to make it more conducive to immune activity. By targeting both the tumor and the immune system, the research seeks to improve treatment outcomes for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer, particularly those who have undergone surgery.
Not a fit: Patients with other types of breast cancer or those who are not eligible for surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for triple-negative breast cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using platelet-mediated delivery systems for cancer therapies, indicating potential for success in this novel approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Hu, Quanyin — University of Wisconsin-Madison
- Study coordinator: Hu, Quanyin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.